Merger & Acquisitions Acceleron Pharma has recently been involved in multiple high-value acquisitions by major players like Merck, presenting sales opportunities for complementary product offerings or services.
Drug Launches The launch of Reblozyl for MDS treatment by Acceleron Pharma indicates potential collaborations for distribution or co-promotion, leading to sales expansion possibilities in the pharmaceutical market.
Partnerships Strategic partnerships with industry leaders like Merck highlight avenues for joint sales and marketing efforts, leveraging each other's strengths for mutual growth and market penetration.
Legal Concerns Legal issues faced by Acceleron Pharma present opportunities for legal services providers to offer support, advice, and consultation, potentially leading to client acquisition and revenue generation.
Asset Sales The sale of assets to Merck for a significant amount suggests potential openings for suppliers or service providers to engage with both companies, offering solutions that enhance operational efficiency or value creation.
587
$50M$100M
6.1K$1B
966$100M$1B
5K$100M$1B
3.6K$100M$1B
1.5K$1B
334$50M$100M
1.5K$100M$1B
585$50M$100MAcceleron Pharma uses 8 technology products and services including SiteCatalyst, GitHub, SAP, and more. Explore Acceleron Pharma's tech stack below.
| Acceleron Pharma Email Formats | Percentage |
| FLast@acceleronpharma.com | 93% |
| First.Last@acceleronpharma.com | 4% |
| Last@acceleronpharma.com | 2% |
| FMiddleLast@acceleronpharma.com | 1% |
Biotechnology ResearchMassachusetts, United States201-500 Employees
Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com
Company Overview
Media & News
Funding & FinancialsAcceleron Pharma has raised a total of $493M of funding over 15 rounds. Their latest funding round was raised on Jun 30, 2020 in the amount of $493M.
Acceleron Pharma's revenue is in the range of $50M$100M
Funding & FinancialsAcceleron Pharma has raised a total of $493M of funding over 15 rounds. Their latest funding round was raised on Jun 30, 2020 in the amount of $493M.
Acceleron Pharma's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com